# OnCo record nct04442022 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04442022/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04442022", "NCT04442022" ;
  schema:name "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly"@en ;
  schema:description "A phase 2/3 trial of Selinexor, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04442022/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04442022> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2020-09-03" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/karyopharm/> .